Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120520703 | 12052070 | 3 | F | 20151108 | 20160630 | 20160209 | 20160707 | EXP | AT-ASTRAZENECA-2016SE11389 | ASTRAZENECA | 16.00 | YR | F | Y | 0.00000 | 20160707 | MD | AT | AT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120520703 | 12052070 | 1 | PS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 0 | 200 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 120520703 | 12052070 | 2 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 0 | 200 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 120520703 | 12052070 | 3 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 0 | 200 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 120520703 | 12052070 | 4 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 0 | 200 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 120520703 | 12052070 | 5 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 0 | 200 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 120520703 | 12052070 | 6 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 0 | 200 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 120520703 | 12052070 | 7 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 0 | 200 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 120520703 | 12052070 | 8 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 0 | 200 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 120520703 | 12052070 | 9 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 0 | 700 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 120520703 | 12052070 | 10 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 0 | 700 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 120520703 | 12052070 | 11 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 0 | 700 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 120520703 | 12052070 | 12 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 0 | 700 | MG | PROLONGED-RELEASE TABLET | QD | |||||||
| 120520703 | 12052070 | 13 | SS | ABILIFY | ARIPIPRAZOLE | 1 | Unknown | Y | 0 | 15 | MG | QD | |||||||
| 120520703 | 12052070 | 14 | SS | ABILIFY | ARIPIPRAZOLE | 1 | Unknown | Y | 0 | 10 | MG | QD | |||||||
| 120520703 | 12052070 | 15 | SS | NOZINAN | LEVOMEPROMAZINE | 1 | Unknown | 200 | MG | Y | 0 | 50 | MG | QD | |||||
| 120520703 | 12052070 | 16 | SS | NOZINAN | LEVOMEPROMAZINE | 1 | Unknown | 200 | MG | Y | 0 | 150 | MG | QD | |||||
| 120520703 | 12052070 | 17 | SS | TEMESTA EXP | LORAZEPAM | 1 | Intravenous (not otherwise specified) | Y | 0 | 6 | MG | QD | |||||||
| 120520703 | 12052070 | 18 | SS | TEMESTA EXP | LORAZEPAM | 1 | Oral | Y | 0 | 2.5 | MG | TABLET | QD | ||||||
| 120520703 | 12052070 | 19 | SS | TEMESTA EXP | LORAZEPAM | 1 | Intravenous (not otherwise specified) | Y | 0 | 2 | MG | QD | |||||||
| 120520703 | 12052070 | 20 | C | DEPAKINE | VALPROATE SODIUM | 1 | Unknown | 0 | 600 | MG | QD | ||||||||
| 120520703 | 12052070 | 21 | C | DEPAKINE | VALPROATE SODIUM | 1 | Unknown | INCREASED TILL 1000 MG | 0 | ||||||||||
| 120520703 | 12052070 | 22 | C | GEWACALM | DIAZEPAM | 1 | Unknown | 0 | |||||||||||
| 120520703 | 12052070 | 23 | C | TRUXAL | CHLORPROTHIXENE | 1 | Unknown | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 120520703 | 12052070 | 1 | Personality disorder |
| 120520703 | 12052070 | 2 | Post-traumatic stress disorder |
| 120520703 | 12052070 | 3 | Chronic tic disorder |
| 120520703 | 12052070 | 4 | Urinary retention |
| 120520703 | 12052070 | 5 | Personality disorder |
| 120520703 | 12052070 | 6 | Post-traumatic stress disorder |
| 120520703 | 12052070 | 7 | Chronic tic disorder |
| 120520703 | 12052070 | 8 | Urinary retention |
| 120520703 | 12052070 | 9 | Personality disorder |
| 120520703 | 12052070 | 10 | Post-traumatic stress disorder |
| 120520703 | 12052070 | 11 | Chronic tic disorder |
| 120520703 | 12052070 | 12 | Urinary retention |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 120520703 | 12052070 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 120520703 | 12052070 | Abdominal pain lower | |
| 120520703 | 12052070 | Micturition urgency | |
| 120520703 | 12052070 | Off label use | |
| 120520703 | 12052070 | Product use issue | |
| 120520703 | 12052070 | Urinary retention |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 120520703 | 12052070 | 1 | 20151108 | 0 | ||
| 120520703 | 12052070 | 2 | 20151108 | 0 | ||
| 120520703 | 12052070 | 3 | 20151108 | 0 | ||
| 120520703 | 12052070 | 4 | 20151108 | 0 | ||
| 120520703 | 12052070 | 5 | 20151109 | 0 | ||
| 120520703 | 12052070 | 6 | 20151109 | 0 | ||
| 120520703 | 12052070 | 7 | 20151109 | 0 | ||
| 120520703 | 12052070 | 8 | 20151109 | 0 | ||
| 120520703 | 12052070 | 13 | 20151105 | 20151108 | 0 | |
| 120520703 | 12052070 | 14 | 20151109 | 20151111 | 0 | |
| 120520703 | 12052070 | 15 | 20151106 | 20151106 | 0 | |
| 120520703 | 12052070 | 16 | 20151107 | 20151107 | 0 | |
| 120520703 | 12052070 | 17 | 20151105 | 0 | ||
| 120520703 | 12052070 | 18 | 20151107 | 20151107 | 0 | |
| 120520703 | 12052070 | 19 | 20151108 | 20151111 | 0 | |
| 120520703 | 12052070 | 20 | 20151108 | 0 |